Navigation Links
Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment
Date:12/4/2010

FRIDAY, Dec. 3 (HealthDay News) -- Use of androgen suppression therapy for low-risk prostate cancer fell after doctors starting receiving lower Medicare payments for the treatment, but use of the treatment for patients with metastatic prostate cancer stayed steady, a new study shows.

The findings, published online Dec. 3 in the Journal of the National Cancer Institute, suggest the payment cuts may have reduced over-treatment of low-risk prostate cancer, the researchers said.

Between 1991 and 1999, the use of the therapy for prostate cancer increased more than threefold among patients with metastatic prostate cancer (cancer that has spread) and low-risk prostate cancer, even though the treatment has not been shown to improve survival in patients with low-risk disease.

When Medicare physician reimbursements for androgen therapy were reduced by 64 percent between 2004 and 2005, use of the therapy for men with low-risk prostate cancer fell by 40 percent while there was no statistically significant change among men with metastatic prostate cancer, the study found.

The researchers looked at factors other than Medicare payment cuts that could account for the findings, such as growing awareness of the therapy's side effects and increasing use of longer-acting treatments.

However, they concluded that the decline in use of androgen therapy for low-risk prostate cancer patients "likely represents a real effect of reimbursement change and not physician awareness of clinical evidence," wrote Dr. Sean P. Elliott, of the University of Minnesota, and colleagues in a news release from the journal.

More information

The American Urological Association has more about hormone therapy for prostate cancer.

-- Robert Preidt

SOURCE: Journal of the National Cancer Institute, news release, Dec. 3, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts
2. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
3. Medicare Part D Changes Not Overwhelming, Experts Say
4. Study shows drop in unnecessary care after Medicare reimbursement cut
5. Use of Prostate Cancer Treatment Fell When Medicare Paid Docs Less
6. Study identifies flaws in Medicare prescription drug program
7. Investment in CRC screening targeting pre-medicare population could cut medicare treatment costs
8. New Medicare model guidelines for benefit years 2012-2014 in development
9. Drug coverage under Medicare leads to increased use of antibiotics
10. Regional variation in health-care spending and utilization higher in Medicare than private sector
11. Study: Medicare policy may account for growing length of hospice stays in nursing homes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, ... University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) ... program, developed in association with efforts by the American College of Surgeons, U.S. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... laboratory instruments are critical to ensuring high-quality results and maintaining GMP and USP ... of Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology: